drugset / Trial / NCT04150029
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
NaSequentialOpen-labelTreatment
Summary
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2024-10-25
- Completion
- 2024-10-25
Outcome
Outcome not reported
Stopped: “Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sabatolimab | Monoclonal antibody | — | Intravenous |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |
| Background | Venetoclax | Small molecule | — | Oral |